AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00880958 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mixture of various probiotics and fermentation products
Study NCT00880958 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00787176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group D 125 mL/hr lactated ringers oxytocin decreased to 1/2 current rate
Description: The maintenance infusion of 125 mL/hr of Lactated Ringers was given with no additional fluid bolus. The dose of oxytocin being administered at time of epidural placement will be halved and not increased for 60 minutes until after placement.
Study NCT04094584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vivitrol (Extended Release Naltrexone)
Description: Monthly Injections of 380mg Extended-Release Naltrexone, case management services as needed tailored to the individual participant
Study NCT01189305 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Couples Therapy
Description: Behavioral Couples Therapy
Study NCT01625988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2951742
Study NCT01189305 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Drug Counseling
Description: Individual Drug Counseling
Study NCT02717130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Study NCT04777266 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music therapy and treatment as usual
Description: The session-based intervention programme was designed with an integrated and multimodal perspective of music therapy \[37\], which allows the combination of active and passive activities together with focuses and perspectives based on empirical evidence \[38\]. It was implemented using a process-based approach, adapting content to different phases in the process: initial contact, managing resistance, confidence building, relationships, awareness, and closure. The central focus is on the patient and to adapt and remain flexible in the sessions in accordance with the capabilities and needs of the group members. Different perspectives are integrated via nonverbal communication. The layout and any changes to the setting are made in a gradual way in keeping with the process to foster feelings of security and belonging. Sessions begin with a brief period of breathing which then moves into warming-up and free-expression using instruments, followed by the central activity and the closure.
Study NCT02264847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human chorionic gonadotrophin
Description: Once a follicle reached more than 18 mm in size,women assigned to group (1) received 5,000 IU hCG trigger in the morning between 9 and 10 a.m. and the couple were advised to have intercourse the following night, about 36 hours later.
Study NCT02264847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clomiphene citrate alone
Description: clomiphene citrate alone without hCG trigger
Study NCT04777266 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music therapy and treatment as usual
Description: The session-based intervention programme was designed with an integrated and multimodal perspective of music therapy \[37\], which allows the combination of active and passive activities together with focuses and perspectives based on empirical evidence \[38\]. It was implemented using a process-based approach, adapting content to different phases in the process: initial contact, managing resistance, confidence building, relationships, awareness, and closure. The central focus is on the patient and to adapt and remain flexible in the sessions in accordance with the capabilities and needs of the group members. Different perspectives are integrated via nonverbal communication. The layout and any changes to the setting are made in a gradual way in keeping with the process to foster feelings of security and belonging. Sessions begin with a brief period of breathing which then moves into warming-up and free-expression using instruments, followed by the central activity and the closure.
Study NCT02686476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin
Description: group I (n = 50): T2DM patients receiving standard care for T2DM (metformin, sulfonylurea, DPP-4 inhibitor or insulin, in any combination) plus 10 mg of Empagliflozin per day
Study NCT01030874 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication review
Description: Current scheduled and as needed medications will be reviewed. Those medications with potentially hypotensive actions will be identified. There will be a joint review by Provider, Pharmacist, and Research staff of those medications and the patient's current clinical status. Plan to continue, decrease, discontinue, or substitute will be made. Examples include substitution of tamsulosin for prazosin in treating benign prostatic hypertrophy, reduction of furosemide dose for patient with stable congestive heart failure, change of sleeping medication from trazodone to lorazepam or zolpidem; change of antidepressant therapy or neuroleptic therapy to one with less hypotensive effects.(Mader 1989); (Poon and Braun 2005);(Mader 2006); (2008).
Study NCT01030874 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition/Salt intake
Description: Current diet orders and meal consumption will be reviewed for sodium and fluid intake. Liberalization of calories, fluid, addition of salt packets to tray, or addition of salty foods/beverages (V8) will be considered as appropriate. Subjects receiving tube feedings will have water flushes replaced with saline flushes. Subjects with a history of congestive heart failure will be liberalized slowly and monitored closely by both the research and treatment team.
Study NCT01030874 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: The research intervention staff will review symptoms of OH with patient/family and explain pathophysiology using a standardized pt information handout (NINDS 2007), subjects will be encouraged to spend maximal time out of bed, and to ambulate on ward as much as possible.
Study NCT01030874 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The patient's PT and/or Provider will review patient function for the ability to perform appropriate exercises and train patients (Ten Harkel, van Lieshout et al. 1994); (Bouvette, McPhee et al. 1996). Research staff will reinforce using these exercises while standing.
Study NCT01030874 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drug Recommendations
Description: The protocol permits the study physician to recommend medications for orthostatic hypotension. The patient's clinical team can implement, ignore, or modify these recommendations and only the clinical team can write orders for them. Fludrocortisone may be given 0.05mg at bedtime up to 0.2mg twice a day (Ten Harkel, Van Lieshout et al. 1992). Subjects with a history of congestive heart failure or peripheral edema will be carefully monitored. Sodium chloride tablets may be given starting at 1gm daily and increased to 2 gms twice daily \[Mukai 2002; Grubb 2003\]. Subjects with a history of congestive heart failure or peripheral edema will be carefully reviewed and monitored closely by the research staff and the treatment team. Midodrine may be given 2.5-5mg daily to three times daily \[Low, 1997\]. The dose will be started at 2.5mg every morning and then increased to 5mg every morning, then 5mg every morning and afternoon, then 5mg three times a day.
Study NCT01767272 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: fexofenadine
Description: fexofenadine brand name
Study NCT01775657 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thopaz (Digital drainage)
Study NCT01775657 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thopaz (Digital drainage)
Study NCT01775657 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pleur Evac (Analogue drainage)
Study NCT01625988 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02784561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan (Zhejiang Otsuka Pharmaceutical Co. Ltd)
Description: busulfan (3.2 mg/kg/day intravenously \[i.v.\], days -10 to -8)
Study NCT02784561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine(Actavis Italy S.p.A)
Description: cytarabine (1.6 g/m2/day, days -7 to -3)
Study NCT02784561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine (Bayer)
Description: fludarabine (30 mg/m2, day -7 to -3),
Study NCT00549770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Study NCT00549770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Study NCT02784561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: granulocyte colony-stimulating factor (KirinKunpeng)
Description: granulocyte colony-stimulating factor (5 ug/kg, day -8 to granulocyte recovery)
Study NCT02784561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabbit ATG（Sanofi/Genzyme）
Description: ATG; thymoglobuline, rabbit;2.5 mg/kg/day, days -5 to -2
Study NCT00549770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AHU377
Study NCT00549770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT00549770 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00549770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT03624452 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rIPC + Exercise
Description: The interventions consist of exercise training on a static bike three times per week and/or three bouts of rIPC per week for 8 weeks. A single bout of rIPC consists of cycles of upper arm cuff inflation for 5 minutes, followed by 5 minutes cuff deflation repeated 4 times.
Study NCT03624452 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rIPC only
Description: Three bouts of rIPC per week for 8 weeks. A single bout of rIPC consists of cycles of upper arm cuff inflation for 5 minutes, followed by 5 minutes deflation repeated 4 times.
Study NCT03394157 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: metabolic surgery
Description: operation to cure type2 diabetes
Study NCT02521272 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing in the simulated avalanche snow.
Description: Breathing in the simulated avalanche snow with zero air pocket and one-liter air pocket.
Study NCT02521272 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: air pocket
Description: Zero air pocket or one-liter air pocket in the snow.
Study NCT01682811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1 Levulan injection
Description: Control or treatment lesions will be injected with Levulan vehicle only or active drug and incubated under occlusion for 3 or 24 hrs. A minimum of three lesions per group on the same subject will be treated. Lesions will then be excised in the normal manner, sectioned vertically, and checked for Protoporphyrin IX using fluorescence microscopy.
Study NCT01682811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1 Levulan surface application
Description: Control or treatment lesions will be painted with Levulan vehicle only or active drug, allowed to dry, and incubated under occlusion for 3 or 24 hrs. A minimum of three lesions per group on the same subject will be treated. Lesions will then be excised in the normal manner, sectioned vertically, and checked for Protoporphyrin IX using fluorescence microscopy.
Study NCT01682811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1 Levulan surface application twice
Description: Control or treatment lesions will be painted twice with Levulan vehicle only or active drug, allowed to dry between and after applications, and incubated under occlusion for 3 hrs. A minimum of three tumors per group on the same subject will be treated. Lesions will then be excised in the normal manner, sectioned vertically, and checked for Protoporphyrin IX using fluorescence microscopy.
Study NCT02283307 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced contrast DECT scan
Description: Subjects will undergo a dual energy CT scan with reduced contrast
Study NCT02283307 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard contrast SECT scan
Description: Subjects will undergo standard of care single energy CT scan with a standard dose of contrast. (control)
Study NCT00547040 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT01259453 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccination to prevent hepatitis B virus infection
Description: Standard dosing with Twinrix; comparison of standard and acceleration dosing schedule
Study NCT04293302 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT01775657 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pleur Evac (Analogue drainage)
Study NCT03507049 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: iFuse
Description: ifuse will be implanted as described in section on the active comparator arm of the study.
Study NCT03507049 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham group
Description: sham surgery will be performed as desrcribed in section on sham comparator.
Study NCT03507049 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: fMRI study
Description: Quantitative sensory testing, cerebral MRI and functional MRI will be done to examine pain mechanism and activation in the central nervous system.
Study NCT03056209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KL1333 25 mg
Description: oral administration, single dose, 25 mg 1 tab
Study NCT03056209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KL1333 50 mg
Description: oral administration, single dose, 25 mg 2 tabs
Study NCT03056209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KL1333 100 mg
Description: oral administration, single dose, 100 mg 1 tab
Study NCT03056209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KL1333 200 mg
Description: oral administration, single dose, 100 mg 2 tabs
Study NCT03056209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KL1333 400 mg
Description: oral administration, single dose, 100 mg 4 tabs
Study NCT03056209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KL1333 600 mg
Description: oral administration, single dose, 100 mg 6 tabs
Study NCT03056209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KL1333 800 mg
Description: oral administration, single dose, 100 mg 8 tabs
Study NCT03056209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral administration, placebo
Study NCT00751335 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP with ThermoSmart, then CPAP without ThermoSmart
Description: CPAP with ThermoSmart is the application of CPAP with heated humidification and a heated breathing tube.~CPAP without ThermSmart is the application of CPAP with heated humidification without a heated breathing tube.
Study NCT00751335 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP without ThermoSmart, then CPAP with ThermoSmart
Description: CPAP with ThermoSmart is the application of CPAP with heated humidification and a heated breathing tube.~CPAP without ThermSmart is the application of CPAP with heated humidification without a heated breathing tube.
Study NCT02357524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oritavancin
Study NCT01001884 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: caregiver psychoeducational consultation program (CPCP)
Description: 6-session caregiver psychoeducational consultation program (CPCP)
Study NCT04763824 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telementoring with Practice Facilitation
Description: We are attempting to provide education and encourage practice change
Study NCT04763824 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telementoring with Practice Facilitation
Description: We are attempting to provide education and encourage practice change
Study NCT01422395 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Freezing
Description: Vitrification
Study NCT02552537 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: patients with walnut allergy will be exposed during 5 days before food challenge with Omeprazole
Study NCT02552537 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: patients with walnut allergy will be exposed during 5 days before food challenge with Placebo
Study NCT02501486 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ACTH stimulation test
Description: An ACTH stimulation test will be done
Study NCT01871428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aleglitazar
Description: 150 mcg orally daily
Study NCT01871428 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching aleglitazar placebo orally daily
Study NCT04352244 — intervention group
Intervention type: PROCEDURE
Intervention: Fat biopsy
Description: The fat biopsy is performed during a scheduled procedure at the Beth Israel Deaconess Medical Center (BIDMC). Routine preoperative procedures will be followed, including local anesthesia (numbing a particular region of the body) or general anesthesia (being put to sleep).~Adipose tissue will be sampled from different depots depending on the procedure. For example, the surgeon will collect adipose tissue from the neck and supraclavicular depots from cervical spine, thyroid, and parathyroid procedures; perinephric fat from adrenalectomies, omental fat from abdominal procedures, and paraspinal fat from lumbar spine procedures. Up to 5 pieces of fat tissue weighing about three to six grams will be removed. All other aspects of the surgical procedure will proceed as planned. Samples will be prepared for subsequent laboratory analysis.
Study NCT04352244 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: A blood sample will be collected in the fasting state either during preoperative testing or in the preoperative area on the day of planned procedure for measurement of adipose functional markers (leptin, adiponectin) and insulin resistance (insulin, C-peptide), and measures of glycemia (glucose, hemoglobin A1c).
Study NCT04352244 — intervention group
Intervention type: GENETIC
Intervention: Blood sample for DNA analysis
Description: Targeted resequencing of DNA to identify variants associated with adipose phenotypes will be performed.
Study NCT04313595 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RespirHó
Description: The system is a wearable, unobtrusive inertial-sensor-based device for long-term breathing pattern monitoring, also during daily life activities. It consists of three IMU-sensor units (3-axis accelerometer, 3-axis gyroscope, 3-axis magnetometer), positioned respectively on the patient's abdomen and thorax, and on a body area integral with thorax but not affected by espiratory movements. The peripheral units, placed on thorax and abdomen are used to record orientation changes during respiratory movements. The third unit is a central reference unit (hereafter CRU) that receives data from the other two units, save them on an SD card and communicate via Bluetooth with a smartphone / tablet / PC. Moreover, this unit detects only non-respiratory movement, representing not only a pure source of noise that must be removed from the thoracic and bdominal signals, but also a pure source of additional information regarding the state of ctivity of the subject .
Study NCT01218477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Oral tablets, 100-140 mg once daily, depending on cohort (100 mg for those with chronic myeloid leukemia \[CML\]-chronic phase; 140 mg for those with CML-advanced phase)
Study NCT01218477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-833923
Description: Oral capsules, 50-200 mg, depending on cohort (100 mg for those with CML-chronic phase; 140 mg for those with CML-advanced phase)
Study NCT03941327 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: AxoGuard Nerve Cuff
Description: A porcine collagen implant will be used to make a protective sheath around the participant's exposed spinal accessory nerve during surgery. This will be performed by physically wrapping the exposed nerve with the implant and suturing the ends together. The goal is to protect nerve from adhesions and compression in the absence of normal protective lymphatic soft tissue.
Study NCT03941327 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AxoGuard Nerve Cuff
Description: A porcine collagen implant will be used to make a protective sheath around the participant's exposed spinal accessory nerve during surgery. This will be performed by physically wrapping the exposed nerve with the implant and suturing the ends together. The goal is to protect nerve from adhesions and compression in the absence of normal protective lymphatic soft tissue.
Study NCT01017211 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: auricular acupuncture
Description: Experimental group to receive ear needles in the Battlefield Acupuncture points.~Sham group to receive ear needles at points thought to be ineffective but standardized.
Study NCT01017211 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: auricular acupuncture
Description: Experimental group to receive ear needles in the Battlefield Acupuncture points.~Sham group to receive ear needles at points thought to be ineffective but standardized.